Literature DB >> 2448308

Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway.

H Takayama1, G Trenn, M V Sitkovsky.   

Abstract

The mechanism of the cAMP involvement in regulation of cellular functions was studied here using a novel functional assay (antigen receptor-triggered exocytosis of granules) of cloned cytotoxic T lymphocytes (CTL). We suggest that cAMP-dependent protein kinase, protein kinase A, counteracts the protein kinase C and Ca2+-mediated stimulatory T-cell antigen receptor (TcR)-triggered biochemical pathway. This suggestion is supported by experimental results which satisfy criteria for protein kinase A involvement in cellular functions. Pretreatment of CTL with cholera toxin induces cAMP accumulation in CTL, partially inhibits TcR-triggered "lethal hit" delivery to the target cell, and almost completely blocks TcR-triggered exocytosis of granules from CTL. Other agents that raise the intracellular level of cAMP, including forskolin and isobutylmethylxanthine (IBMX) also inhibit TcR-triggered CTL activation. Involvement of cAMP-dependent protein kinase in an inhibitory pathway is suggested by the synergistic effects of cyclic nucleotide analogs 8-bromo-cAMP and N6-benzoyl-cAMP in inhibition of TcR-triggered exocytosis. Forskolin and IBMX inhibited TcR-triggered phosphoinositide turnover in CTL, suggesting that cAMP affected very early events in signal transduction that follow TcR cross-linking by a ligand. The ability of IBMX to inhibit CTL activation when the TcR cross-linking step was by-passed by the combination of phorbol myristate acetate and ionophore A23187 suggests that the locus of inhibitory effect of cAMP is at both the early and late stages of the TcR-triggered transmembrane signaling pathway.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448308

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Sympathetic modulation of immunity: relevance to disease.

Authors:  Denise L Bellinger; Brooke A Millar; Sam Perez; Jeff Carter; Carlo Wood; Srinivasan ThyagaRajan; Christine Molinaro; Cheri Lubahn; Dianne Lorton
Journal:  Cell Immunol       Date:  2008-03-04       Impact factor: 4.868

Review 2.  Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

Authors:  Michail V Sitkovsky; Stephen Hatfield; Robert Abbott; Bryan Belikoff; Dmitriy Lukashev; Akio Ohta
Journal:  Cancer Immunol Res       Date:  2014-07       Impact factor: 11.151

3.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

Review 4.  A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.

Authors:  Stephen M Hatfield; Michail Sitkovsky
Journal:  Curr Opin Pharmacol       Date:  2016-07-17       Impact factor: 5.547

Review 5.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.

Authors:  Bruce N Cronstein; Michail Sitkovsky
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

6.  Dissociation between phytohaemagglutinin-stimulated generation of inositol phosphates and Ca2+ increase in human mononuclear leucocytes.

Authors:  M C Michel; L J van Tits; G Trenn; J Sykora; O E Brodde
Journal:  Biochem J       Date:  1992-07-01       Impact factor: 3.857

Review 7.  Neuroendocrine regulation of inflammation.

Authors:  Caroline J Padro; Virginia M Sanders
Journal:  Semin Immunol       Date:  2014-01-31       Impact factor: 11.130

8.  Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes.

Authors:  B Hofmann; P Nishanian; T Nguyen; P Insixiengmay; J L Fahey
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

Review 9.  Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.

Authors:  Michail Sitkovsky; Akio Ohta
Journal:  J Mol Med (Berl)       Date:  2013-01-20       Impact factor: 4.599

10.  Modulation of T-cell activation through protein kinase C- or A-dependent signalling pathways synergistically increases human immunodeficiency virus long terminal repeat induction by cytomegalovirus immediate-early proteins.

Authors:  C V Paya; J L Virelizier; S Michelson
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.